Pharma companies will continue to push for diversity, experts say

The removal of pages linking to diversity in clinical trials and healthcare is “disappointing”, according to pharma experts who believe the industry will continue as normal due to the scientific justification for improving diversity in clinical trials.

Clinical trial diversity has been a notable talking point recently, with sponsors pushing to make more inclusive and diverse research studies. Despite this, one of the first executive orders that President Donald Trump signed upon entering the White House on 20 January was to end what he termed “radical and wasteful” government diversity, equity and inclusion (DEI) programmes.